Illumina stock holds steady as its sequencing franchise stays central

Illumina stock centers on gene sequencing, life-science tools, and clinical research workflows. The company remains a key US-listed name for investors tracking diagnostics and genomics.

Illumina Inc. (ISIN US4523271090) remains one of the best-known names in gene sequencing, with its business built around instruments, consumables, and software for genomic analysis. The company trades on Nasdaq and serves research, clinical, and applied markets through its sequencing platforms.

Business model

Illumina's core revenue engine comes from sequencing systems and the recurring consumables used with them, a structure that gives the company a different profile from one-time equipment vendors. That mix matters because recurring reagent sales tend to be more closely tied to installed-base utilization than to a single launch cycle.

US market anchor

For US investors, Illumina is a Nasdaq-listed genomics company with direct exposure to the broader life-sciences and diagnostics complex. That makes the name relevant not only to biotech coverage, but also to investors comparing growth rates across US health-care technology peers.

Sequencing franchise

Illumina's product set is centered on high-throughput sequencing systems and the consumables that support them, including the company's flagship platforms for large-scale genetic analysis. In practical terms, that gives the group a hardware-plus-recurrence profile that investors often treat differently from pure instrument makers.

Trading context

Illumina stock trades on Nasdaq in US dollars. As of July 11, 2026, 4:00 p.m. ET, the share price and market-cap snapshot can be tracked on the company's market listings and quote pages used by investors in the US market.

Illumina stock facts

• Company: Illumina Inc.
• ISIN: US4523271090
• Ticker: ILMN
• Exchange: Nasdaq
• Sector / Industry: Health Care / Life Sciences Tools & Services